Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests
Cătălin Roșioru
International Association for the Study of Lung Cancer Sep 8 2025 Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile. Despite complete surgical resection (R0), early-stage NSCLC carries a substantial risk of recurrence and remains a
din zilele anterioare